Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma

Klaus Brasso, Ib Jarle Christensen, Julia S. Johansen, Børge Teisner, Patrick Garnero, Paul A. Price, Peter Iversen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

Resumé

Udgivelsesdato: april 2006
OriginalsprogEngelsk
TidsskriftThe Prostate
Vol/bind66
Udgave nummer5
Sider (fra-til)503-513
DOI
StatusUdgivet - 1. apr. 2006

Fingeraftryk

Alkaline Phosphatase
Prostate
Serum
Estrogens
Multivariate Analysis
Neoplasms

Citer dette

Brasso, K., Christensen, I. J., Johansen, J. S., Teisner, B., Garnero, P., Price, P. A., & Iversen, P. (2006). Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. The Prostate, 66(5), 503-513. https://doi.org/10.1002/pros.20311
Brasso, Klaus ; Christensen, Ib Jarle ; Johansen, Julia S. ; Teisner, Børge ; Garnero, Patrick ; Price, Paul A. ; Iversen, Peter. / Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. I: The Prostate. 2006 ; Bind 66, Nr. 5. s. 503-513.
@article{f6f4dfc0ddf911db9628000ea68e967b,
title = "Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma",
abstract = "BACKGROUND: To examine the prognostic value of markers of bone metabolism (serum PINP, BAP, and CTX-I) and serum YKL-40 in metastatic prostate carcinoma (PC). METHODS: The biomarkers were determined by ELISAs in 153 metastatic PC patients before treatment with parenteral estrogen or total androgen ablation. The median follow-up was 4.9 years. One hundred fifteen patients died. RESULTS: The biomarkers were increased in the patients compared to controls (P < 0.001), and related to performance status and Soloway score (except YKL-40), but not to T-category and WHO tumor grade. PINP was elevated in 87{\%}, BAP (55{\%}), CTX-I (33{\%}), and YKL-40 (43{\%}). Univariate analysis showed an association to survival: PINP (HR = 1.6, P < 0.0001), BAP (HR = 1.4, P < 0.0001), CTX-I (HR = 1.7, P < 0.0001), and YKL-40 (HR = 1.4, P = 0.004). In multivariate Cox analysis performance status, WHO grade, Soloway score, PINP, and YKL-40 were independently predictive factors. CONCLUSIONS: High serum PINP, BAP, CTX-I, and YKL-40 are associated with poor outcome of metastatic PC patients.",
author = "Klaus Brasso and Christensen, {Ib Jarle} and Johansen, {Julia S.} and B{\o}rge Teisner and Patrick Garnero and Price, {Paul A.} and Peter Iversen",
note = "Paper id:: PMID: 16372331 [PubMed - indexed for MEDLINE]",
year = "2006",
month = "4",
day = "1",
doi = "10.1002/pros.20311",
language = "English",
volume = "66",
pages = "503--513",
journal = "The Prostate",
number = "5",

}

Brasso, K, Christensen, IJ, Johansen, JS, Teisner, B, Garnero, P, Price, PA & Iversen, P 2006, 'Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma', The Prostate, bind 66, nr. 5, s. 503-513. https://doi.org/10.1002/pros.20311

Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. / Brasso, Klaus; Christensen, Ib Jarle; Johansen, Julia S.; Teisner, Børge; Garnero, Patrick; Price, Paul A.; Iversen, Peter.

I: The Prostate, Bind 66, Nr. 5, 01.04.2006, s. 503-513.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

TY - JOUR

T1 - Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma

AU - Brasso, Klaus

AU - Christensen, Ib Jarle

AU - Johansen, Julia S.

AU - Teisner, Børge

AU - Garnero, Patrick

AU - Price, Paul A.

AU - Iversen, Peter

N1 - Paper id:: PMID: 16372331 [PubMed - indexed for MEDLINE]

PY - 2006/4/1

Y1 - 2006/4/1

N2 - BACKGROUND: To examine the prognostic value of markers of bone metabolism (serum PINP, BAP, and CTX-I) and serum YKL-40 in metastatic prostate carcinoma (PC). METHODS: The biomarkers were determined by ELISAs in 153 metastatic PC patients before treatment with parenteral estrogen or total androgen ablation. The median follow-up was 4.9 years. One hundred fifteen patients died. RESULTS: The biomarkers were increased in the patients compared to controls (P < 0.001), and related to performance status and Soloway score (except YKL-40), but not to T-category and WHO tumor grade. PINP was elevated in 87%, BAP (55%), CTX-I (33%), and YKL-40 (43%). Univariate analysis showed an association to survival: PINP (HR = 1.6, P < 0.0001), BAP (HR = 1.4, P < 0.0001), CTX-I (HR = 1.7, P < 0.0001), and YKL-40 (HR = 1.4, P = 0.004). In multivariate Cox analysis performance status, WHO grade, Soloway score, PINP, and YKL-40 were independently predictive factors. CONCLUSIONS: High serum PINP, BAP, CTX-I, and YKL-40 are associated with poor outcome of metastatic PC patients.

AB - BACKGROUND: To examine the prognostic value of markers of bone metabolism (serum PINP, BAP, and CTX-I) and serum YKL-40 in metastatic prostate carcinoma (PC). METHODS: The biomarkers were determined by ELISAs in 153 metastatic PC patients before treatment with parenteral estrogen or total androgen ablation. The median follow-up was 4.9 years. One hundred fifteen patients died. RESULTS: The biomarkers were increased in the patients compared to controls (P < 0.001), and related to performance status and Soloway score (except YKL-40), but not to T-category and WHO tumor grade. PINP was elevated in 87%, BAP (55%), CTX-I (33%), and YKL-40 (43%). Univariate analysis showed an association to survival: PINP (HR = 1.6, P < 0.0001), BAP (HR = 1.4, P < 0.0001), CTX-I (HR = 1.7, P < 0.0001), and YKL-40 (HR = 1.4, P = 0.004). In multivariate Cox analysis performance status, WHO grade, Soloway score, PINP, and YKL-40 were independently predictive factors. CONCLUSIONS: High serum PINP, BAP, CTX-I, and YKL-40 are associated with poor outcome of metastatic PC patients.

U2 - 10.1002/pros.20311

DO - 10.1002/pros.20311

M3 - Journal article

VL - 66

SP - 503

EP - 513

JO - The Prostate

JF - The Prostate

IS - 5

ER -